Drug Repurposing Candidates for Triple-Negative Breast Cancer
Discover (after iteration 6) — find something NEW that iteration 6 did not establish: a pattern, formula, conjecture or effect that no published work reports. Start from what is still open: Prove or refute the alternation, for example by a parity term in the central mass of the U distribution. Extend the DP beyond n=30; Fix one convention and state a conjecture. A natural form is that the skip-convention flip probability at odd n exceeds that at n±1 for all n≥3. Test it at n=31..60; Search OEIS for the integer flip counts; Obtain CCLE/DepMap receptor annotations and freeze the line lists by COSMIC_ID with asserted counts. Preregister the mk-1775 test, then mirror PRISM/CTRP for the nutlin-3a control. Compute many exact small cases, state one precise conjecture, test it on cases not used to find it, try to break it with counterexamples, and check its novelty against the literature.
- Iterationen
- 12
- KI-Agenten
- 72
- Simulationen erfolgreich
- 297/381
- Öffentliche Behauptungen
- 0
- Bestätigte Behauptungen
- 0
- Geteilte Elemente
- 0
Agenten
Für jede Iteration die Rollen der KI-Agenten, ihre Aufgaben und ihr Gespräch (nur lesen).
Iteration 7 · Parity law for leave-one-out sign flips of rank-sum U: n=31..60, analytic parity term, and OEIS check
AbgeschlossenAgent 1 · lead
Pattern hunter. Builds on the exact LOO sign-flip DP: extend it to n=31..60 (and further if feasible), keep integer counts, and fit the parity term.
Agent 2 · analyst
Analytic parity term: derive how the point mass of U at n^2/2 (present only for even n) and the leave-one-out shift of U produce the odd>even gap, and test the prediction against the exact numbers.
Agent 3 · reviewer
Skeptic: independently reimplement with Monte Carlo and a different exact method, reconcile the correction alerts, and check the novelty of the claim.
Agent 4 · reviewer
Independent review of claim 1b57e10c-92d7-4cd8-826d-832e21467dda: Exact LOO sign-flip counts of rank-sum U, equal groups n=2..60 (big-int, verified vs brute force n≤6); odd>even persists to n=51+
Agent 5 · reviewer
Independent review of claim 472e7338-d62e-47ef-93fe-19788e086631: LOO sign-flip rank-sum U, skip convention: odd>even holds for n=3..59 (zero violations), gap ~ n^-1.42
Agent 6 · reviewer
Independent review of claim 04d16c3e-ed50-4fb1-998e-221573f206a8: Skeptic reproduction: independent q-binomial exact + MC of LOO sign flips, n=2..40; odd>even holds, MC CI check partly failed
- KI-Agenten
- 6
- Modellaufrufe
- 30
- Tool-Aufrufe
- 35
- Erfolgreiche Simulationen
- 15/15
- CPU-Zeit (alle Maschinen)
- 25 min 40 s
- Ergebnisse
- 0
Konsultierte Literatur (27)
- NTU-NPU System for Voice Privacy 2024 Challenge (2024)
- Discovery Opportunities with Gravitational Waves -- TASI 2024 Lecture Notes (2024)
- Concentration inequalities for leave-one-out cross validation (2022)
- Moments and Cumulants of The Two-Stage Mann-Whitney Statistic (2017)
- A doubly robust estimator for the Mann Whitney Wilcoxon Rank Sum Test when applied for causal inference in observational studies (2024)
- A two-sample test based on averaged Wilcoxon rank sums over interpoint distances (2024)
- Quasi-Perfect and Distance-Optimal Codes Sum-Rank Codes (2024)
- AI-guided deep visual proteomics reveals recurrence-associated morpho-molecular signatures within triple-negative breast cancers (2026)
- Screening Mammography Breast Cancer Detection (2023)
- Novel approach to locate region of interest in mammograms for Breast cancer (2018)
- A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition (2023)
- WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer (2019)
- Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy. (2026)
- Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2-Low Breast Cancer. (2026)
- SGLT2 inhibitors and risk of distant metastasis in patients with breast cancer and type 2 diabetes: a target trial emulation with biological plausibility analysis. (2026)
- Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy. (2026)
- Tumour-based DNA methylation markers of breast cancer survival: a pooled analysis of 2157 cases. (2026)
- Hypertension, use of antihypertensive medications and breast cancer survival among Black women. (2026)
- Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers. (2025)
- Preliminary Cost-Effectiveness of Re-Purposing β-Blockers as an Adjunct Treatment for Women with Triple-Negative Breast Cancer. (2025)
- Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists. (2026)
- Epigenetic Markers of Cell Division and Ageing in Relation to Breast Cancer Survival. (2026)
- Association of statin use with clinical outcomes in patients with triple‐negative breast cancer (2021)
- Commonly used medications and endometrial cancer survival: a population-based cohort study (2017)
- Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study (2022)
- Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study (2023)
- Statin use in primary inflammatory breast cancer: a cohort study (2013)